FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023644734> ?p ?o ?g. }

• W2023644734 endingPage "301" @default.
• W2023644734 startingPage "294" @default.
• W2023644734 abstract "Comparar custos e benefícios clínicos de três terapias adicionais à metformina (MF) para pacientes com diabetes mellitus tipo 2 (DMT2). Um modelo de simulação de eventos discretos foi construído para estimar a relação custo-utilidade (custo por QALY) da saxagliptina como uma terapia adicional à MF comparada à rosiglitazona ou pioglitazona. Um modelo de impacto orçamentário (BIM – Budget Impact Model ) foi construído para simular o impacto econômico da adoção de saxagliptina no contexto do Sistema Suplementar de Saúde brasileiro. O custo de aquisição da medicação para o grupo de pacientes hipotéticos analisados, para o horizonte temporal de três anos, foi de R$ 10.850.185,00, R$ 14.836.265,00 e R$ 14.679.099,00 para saxagliptina, pioglitazona e rosiglitazona, respectivamente. Saxagliptina exibiu menores custos e maior efetividade em ambas as comparações, com economias projetadas para os três primeiros anos de -R$ 3.874,00 e -R$ 3.996,00, respectivamente. O BIM estimou uma economia cumulativa de R$ 417.958,00 com o reembolso da saxagliptina em três anos a partir da perspectiva de uma operadora de plano de saúde com 1 milhão de vidas cobertas. Da perspectiva da fonte pagadora privada, a projeção é de que o acréscimo de saxagliptina à MF poupe custos quando comparado ao acréscimo de rosiglitazona ou pioglitazona em pacientes com DMT2 que não atingiram a meta de hemoglobina glicada (HbA1c) com metformina em monoterapia. O BIM, para a inclusão de saxagliptina nas listas de reembolso das operadoras de planos de saúde, indicou uma economia significativa para o horizonte de 3 anos. To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R$ 10,850,185, R$ 14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon." @default.
• W2023644734 created "2016-06-24" @default.
• W2023644734 creator A5001951839 @default.
• W2023644734 creator A5035841283 @default.
• W2023644734 creator A5041857451 @default.
• W2023644734 creator A5046305526 @default.
• W2023644734 creator A5058915530 @default.
• W2023644734 creator A5066180851 @default.
• W2023644734 creator A5067580935 @default.
• W2023644734 creator A5084181582 @default.
• W2023644734 creator A5084351623 @default.
• W2023644734 date "2012-05-01" @default.
• W2023644734 modified "2023-10-04" @default.
• W2023644734 title "Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil" @default.
• W2023644734 cites W1968865647 @default.
• W2023644734 cites W1970125713 @default.
• W2023644734 cites W1971471384 @default.
• W2023644734 cites W1975248655 @default.
• W2023644734 cites W1981113379 @default.
• W2023644734 cites W1984735373 @default.
• W2023644734 cites W1987908917 @default.
• W2023644734 cites W1998531851 @default.
• W2023644734 cites W2003389247 @default.
• W2023644734 cites W2022849871 @default.
• W2023644734 cites W2029095679 @default.
• W2023644734 cites W2031484324 @default.
• W2023644734 cites W2033742425 @default.
• W2023644734 cites W2038962843 @default.
• W2023644734 cites W2047588523 @default.
• W2023644734 cites W2047806427 @default.
• W2023644734 cites W2058088226 @default.
• W2023644734 cites W2062033943 @default.
• W2023644734 cites W2080454816 @default.
• W2023644734 cites W2089770071 @default.
• W2023644734 cites W2092517735 @default.
• W2023644734 cites W2095494599 @default.
• W2023644734 cites W2098289172 @default.
• W2023644734 cites W2101430875 @default.
• W2023644734 cites W2103058881 @default.
• W2023644734 cites W2107380495 @default.
• W2023644734 cites W2114773801 @default.
• W2023644734 cites W2123946565 @default.
• W2023644734 cites W2126065052 @default.
• W2023644734 cites W2126252058 @default.
• W2023644734 cites W2135370151 @default.
• W2023644734 cites W2144085470 @default.
• W2023644734 cites W2150883811 @default.
• W2023644734 cites W2153361130 @default.
• W2023644734 cites W2155826881 @default.
• W2023644734 cites W2159904588 @default.
• W2023644734 cites W2166787593 @default.
• W2023644734 cites W270352310 @default.
• W2023644734 doi "https://doi.org/10.1590/s0104-42302012000300008" @default.
• W2023644734 hasPublicationYear "2012" @default.
• W2023644734 type Work @default.
• W2023644734 sameAs 2023644734 @default.
• W2023644734 citedByCount "11" @default.
• W2023644734 countsByYear W20236447342012 @default.
• W2023644734 countsByYear W20236447342013 @default.
• W2023644734 countsByYear W20236447342014 @default.
• W2023644734 countsByYear W20236447342015 @default.
• W2023644734 countsByYear W20236447342016 @default.
• W2023644734 countsByYear W20236447342020 @default.
• W2023644734 crossrefType "journal-article" @default.
• W2023644734 hasAuthorship W2023644734A5001951839 @default.
• W2023644734 hasAuthorship W2023644734A5035841283 @default.
• W2023644734 hasAuthorship W2023644734A5041857451 @default.
• W2023644734 hasAuthorship W2023644734A5046305526 @default.
• W2023644734 hasAuthorship W2023644734A5058915530 @default.
• W2023644734 hasAuthorship W2023644734A5066180851 @default.
• W2023644734 hasAuthorship W2023644734A5067580935 @default.
• W2023644734 hasAuthorship W2023644734A5084181582 @default.
• W2023644734 hasAuthorship W2023644734A5084351623 @default.
• W2023644734 hasBestOaLocation W20236447341 @default.
• W2023644734 hasConcept C112930515 @default.
• W2023644734 hasConcept C126322002 @default.
• W2023644734 hasConcept C134018914 @default.
• W2023644734 hasConcept C151730666 @default.
• W2023644734 hasConcept C160735492 @default.
• W2023644734 hasConcept C162324750 @default.
• W2023644734 hasConcept C2777180221 @default.
• W2023644734 hasConcept C2778384471 @default.
• W2023644734 hasConcept C2779343474 @default.
• W2023644734 hasConcept C2779703844 @default.
• W2023644734 hasConcept C2780152017 @default.
• W2023644734 hasConcept C2780323712 @default.
• W2023644734 hasConcept C2910068830 @default.
• W2023644734 hasConcept C29456083 @default.
• W2023644734 hasConcept C2992755240 @default.
• W2023644734 hasConcept C3019080777 @default.
• W2023644734 hasConcept C50522688 @default.
• W2023644734 hasConcept C555293320 @default.
• W2023644734 hasConcept C71924100 @default.
• W2023644734 hasConcept C86803240 @default.
• W2023644734 hasConceptScore W2023644734C112930515 @default.
• W2023644734 hasConceptScore W2023644734C126322002 @default.
• W2023644734 hasConceptScore W2023644734C134018914 @default.
• W2023644734 hasConceptScore W2023644734C151730666 @default.

• next